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ABSTRACT
Objectives: There are controversies regarding the long-term oncological safety of 
preservation of pelvic innervation during radical hysterectomy (RH). This study aimed 
to analyze the feasibility and safety of nerve-sparing radical hysterectomy (NSRH) 
for cervical cancer compared with non-NSRH following 17 years of experience in a 
tertiary cancer referral center.
Materials and Methods: Between May 1999 and June 2016, all patients who 
underwent RH for cervical cancer were followed-up prospectively. Comparison 
analyses regarding surgical outcomes, complications, overall survival (OS), disease-
free survival (DFS), and cancer-specific survival (CSS) were performed between 
patients treated with NSRH and non-NSRH.
Results: A total of 188 patients were included (113 non-NSRH and 75 NSRH). 
The median follow-up was 112 months. Estimated blood loss and hospital stay were 
all significantly lower in the NSRH group. Overall intraoperative complication rate 
(p = 0.02) and need for transfusion (p = 0.016) were lower in the NSRH group. There 
were no differences in the median operation time, OS, DFS, CSS, or recurrence rates 
between the NSRH and non-NSRH group.
Conclusions: Our study provides a wide perspective on the developments of 
nerve-sparing procedures for the management of women with early-stage cervical 
cancer. Our results suggest that NSRH is a feasible and safe procedure, with reduced 
morbidity outcomes.
INTRODUCTION
Open conventional abdominal radical hysterectomy 
without nerve-sparing has been for many years the 
primary treatment for patients with early stage cervical 
cancer [1, 2]. However, up to 25% of these patients will 
suffer severe reduction in their quality of life secondary 
to bladder, rectal, and sexual dysfunctions following the 
procedure [3]. This is mainly caused by the iatrogenic 
damage of the pelvic nerve plexus during surgery [4, 5].
With the aim to provide an alternative surgical 
technique for these patients, the preservation of pelvic 
innervation during radical hysterectomy (RH) was 
developed in Japan in the early 1920s [6]. This technique 
evolved in the 1960s by adding the division of the 
paracervix into its vascular and neural components, as 
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well as sparing the nerve bundle when sectioning the 
uterosacral ligament [7]. This technique, called nerve-
sparing RH (NSRH), was later expanded, allowing for the 
preservation of the splanchnic nerves (parasympathetic 
innervation), inferior hypogastric nerves (sympathetic 
innervation), and vesical branch of the lower hypogastric 
plexus during the dissection of the paracervical tissue. 
Initially, the use of NSRH was limited because of 
the difficulties in the identification of the anatomical 
structures and the lack of data regarding its oncological 
safety. In fact, it was not until 2008 that NSRH was 
first introduced in a standardized RH classification 
[8]. Progressively, it was adopted by some European 
centers [9–15] and over the last decade, it is has become 
more commonly performed in the USA by gynecologic 
oncologists following the widespread use of robotic 
technology.
However, as reflected by a recent systematic review, 
some groups still hesitate to introduce minimally invasive 
surgery (MIS) for NSRH, arguing that the heterogeneity 
in surgical techniques and the quality and volume of 
published literature prevents a high degree of certainty 
regarding both oncologic safety and quality of life 
improvement, compared with conventional RH [16].
We present the results from our institution of a 
study with one of the longest follow-up duration to date 
and analyze how the introduction of a nerve-sparing 
technique during RH has influenced the surgical and 
oncologic outcomes of these patients. This study aimed 
to analyze the feasibility and safety results of NSRH for 
cervical cancer compared with conventional RH following 
17 years of experience in a tertiary cancer referral center.
RESULTS
Between May 1999 and October 2006, a total of 
188 patients diagnosed with early-stage cervical cancer 
underwent RH in our institution. Of these patients, 113 
underwent a non-NSRH, 43 (38%) a Piver type II, and 
70 (62%) a Piver type III RH. A nerve-sparing technique 
was carried out in all radical hysterectomies performed 
after October 2006 (n = 75): 30 (40%) with type B1 and 
45 (60%) with type C1. The decision to perform RH in the 
five cases of locally advanced disease (IIB = 2 and IIB2-
IIA2 = 3) was influenced by the patient’s characteristics 
and preferences and agreed by the gynecology-oncology 
team.
The median age was 48.2 (range, 25–77) years with 
a median body mass index of 26.1 (range, 18–40) kg/
m2. The median follow-up was 112 (range, 53.7–162.3) 
months. The predominant histologic type was squamous 
cell carcinoma (61.17%), followed by adenocarcinoma 
(32.4%). Final pathology revealed 16 (8.51%) patients 
with tumors larger than 4 cm (pT1b2-T2a2) and 15 
(7.98%) with microscopic parametrial involvement (pT2b) 
with no significant differences between the NSRH and 
non-NSRH groups. Characteristics of the study population 
and intra-operative data are presented in Tables 1 and 2.
Estimated blood loss (EBL) and hospital stay (HS) 
were all significantly inferior in the nerve-sparing group, 
whereas no differences were found in operative time (OT), 
even when taking into account the surgical approach (open 
or MIS).
Overall intra-operative complication rate (p = 0.02) 
and the need for transfusion (p = 0.02) were significantly 
lower in the NSRH group. The conversion rate to 
laparotomy in the NSRH group was 0%, whereas for the 
non-NSRH it was 3.92%. Morbidity data are detailed in 
Table 3.
The bladder and bowel function were investigated 
at one year after surgery. A total of 7 patients in the 
NSRH group and 22 patients in the non-NSRH presented 
bladder and rectal functional-related complications. The 
results are shown in Table 4. The incidence of urinary 
incontinence and loss of bladder filling sensation was 
significantly lower in the NSRH group compare to 
the non-NSRH group (1.3% vs. 3.5%; 1.3% vs. 5.3%, 
respectively) (p > 0.05).
In terms of oncologic outcomes, there were no 
differences in OS, disease-free survival (DFS), or 
recurrence rates between the NSRH and non-NSRH 
groups (Figure 1). Of the 188 patients, 156 (82.98%) 
where alive and disease-free at the end of the study period, 
that is, 65 (86.67%) in the NSRH group and 91 (80.53%) 
in the non-NSRH group (p = 0.18). Recurrences are 
specified in Table 5. Cancer-specific mortality rate was 
6% for the NSRH and 8.8% for the non-NSRH (p = 0.91).
DISCUSSION
Evidence following publication of different series 
[17, 18] and recent meta-analysis [19, 20] has shown that 
NSRH decreases bladder and rectal dysfunction without 
compromising recurrence or survival rates compared with 
non-NSRH. This study represents one of the longer-term 
follow-up periods published to date in which the results 
for non-NSRH and NSRH are compared with respect to 
surgical and oncologic outcomes. Although over 80% 
of nerve-sparing procedures were performed by MIS, 
there were no differences in terms of surgical time when 
compared with the non-NSRH group. Moreover, within the 
MIS group, NSRH presented with a significant reduction 
in OT. These results differ from those presented in a recent 
meta-analysis [19, 21] in which both laparoscopic and 
abdominal routes presented greater surgical times in the 
nerve-sparing group. This difference could be partially 
explained by the introduction of the RRH in our series, 
which presented with similar surgical times to ORH and 
significantly lower times than LRH, contributing to an 
overall reduced OT in MIS.
Similarly, in our series, NSRH showed significantly 
inferior EBL compared to that of non-NSRH group. It 
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could be argued that the significant difference in EBL 
could be explained by the fact that most NSRH were 
performed by MIS. The reduction in EBL with this 
approach is consistently reported in most studies [22]. 
However, the reduction in EBL is persistent even when 
comparing NSRH with non-NSRH within each of the 
surgical approaches (MIS and ORH). In this regard, the 
accumulative experience of the surgical team as well as 
the progressive introduction of vessel sealer devices could 
partially explain the results [23].
The number of excised pelvic nodes in our series 
is similar to that previously reported in the literature, 
with no differences between the NSRH and non-NSRH 
groups. In two published meta-analysis [19, 24] in which 
NSRH is compared to non-NSRH, the number of excised 
pelvic nodes is not considered a meaningful variable of 
comparison. Regardless, we consider that these results 
would support the oncologic safety of the nerve-sparing 
technique.
In our series, the total paracervix volume resected 
was similar between the NSRH and non-NSRH groups, 
regardless of the surgical approach. These results are 
similar to those presented by other groups [24, 25]. Thus, 
nerve-sparing techniques do not appear to be associated 
with smaller surgical resections in laparoscopic nor open 
procedures.
In our series, we found significant differences in 
vascular injury rates and patients requiring transfusion, 
in favor of the NSRH group. Although our study supports 
the evidence presented in a recent meta-analysis [19] 
regarding the reduction in intraoperative complications 
associated with nerve-sparing techniques, we should 
reconsider the fact that most of the nerve-sparing 
procedures were performed by MIS, which by itself 
is related to fewer intra-operative complications [25]. 
We decided to consider transfusion as a complication 
because it marked a differential management of the 
patients and could be related to greater postoperative 
morbidity.
The NSRH technique improved all the urinary 
symptoms (frequent urination, urinary incontinence, 
difficulty emptying and bladder sensation), which could 
be due to the complete preservation of autonomic nervous 
structure that controls the bladder in the nerve plane 
[26]. Moreover, the full recovery of urinary function 
usually take approximately one year after radical surgery; 
Table 1: Clinical and pathologic data in the NSRH and non-NSRH groups
NSRH
n = 75
Non-NSRH
n = 113
All patients
n = 188 p
Age, years mean (SD) 47 (11.6) 49 (12.8) 48.21 (12.35) 0.27
BMI, median (range) 25 (18–37) 26 (18–40) 26.16 (18–40) 0.21
MS, n (%) 27 (36.49) 42 (37.7) 69 (36.9) 0.92
Previous abdominal surgery, n (%) 30 (52.2) 70 (59.2) 100 (53.1) 0.14
Parity, median (range) 2 (0–6) 2 (0–7) 2 (0–7) 0.52
Histological type, n (%)
Squamous cell carcinoma 44 (58.6) 72 (62.8) 115 (61.2) 0.55
Adenocarcinoma 27 (36) 34 (30.1) 61 (32.4)
Others 4 (5.3) 8 (7.06) 12 (6.38)
Histological grade, n (%)
G1 10 (13.3) 10 (8.85) 20 (10.6) 0.012
G2 44 (58.7) 56 (49.5) 100 (53.2)
G3 21 (28) 33 (29.2) 54 (28.7)
NS 0 14 (12.4) 14 (7.4)
FIGO stage, n (%)
1A2 3 (4) 8 (7.08) 11 (5.85) 0.27
1B1 ≤ 2 cm 27 (36) 34 (30.1) 61 (32.45)
1B1 > 2 cm 34 (45.3) 63 (55.7) 97 (51.6)
IIA1 6 (8) 8 (7.1) 14 (7.45)
IIB 2 (2.67) 0 2 (1.06)
IB2 & IIA2 3 (4) 0 3 (1.6)
BMI, body mass index (kg/m2); MS, menopausal status; Non-NSRH, non-nerve-sparing radical hysterectomy; NSRH, nerve-
sparing radical hysterectomy; NS, not specified; p, p value; SD, standard deviation.
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Table 2: Operative data
Surgery, n (%) NSRHn = 75
Non-NSRH
n = 113
All patients
n = 188 p
Type of RH, n (%) NA
B1 RH 30 (40)
C1 RH 45 (60)
Type II RH 43 (38)
Type III RH 70 (61)
Ovarian preservation, n (%) 28 (37.3) 43 (38.05) 71 (37.1) 0.88
Sentinel node procedure, n (%) 53 (71) 68 (60.1) 121 (64.4) 0.87
Approach, n (%)
LRH 39 (52) 51 (45.1) 90 (47.9)
ORH 14 (18.6) 62 (54.8) 76 (40.4)
RRH 22 (29.3) 0 22 (11.7)
LRH+RRH (MIS) 61 (81.3) 51 (45.1) 112 (59.7)
Extracted pelvic nodes, median (range) 20 (8–49) 20 (5–52) 20 (5–52) 0.95
ORH 21.5 (9–49) 20.5 (5–-52) 0.80
MIS 20 (8–37) 18 (8–51) 0.25
Patients with positive pelvic nodes, n (%) 13 (17.33%) 11 (9.75%) 23 (12.77%) 0.126
Mean total parametrial volume, cm3 (SD) 18.91 (9.62) 20.26 (10.47) 19.68 (10.1) 0.41
Mean operative time, min. (SD) 261 (47.98) 269 (50.7) 266.08 (49.68) 0.27
ORH 239.64 (53.65) 246.05 (38.78) 0.74
MIS 266.19 (45.56) 297.55 (49.37) 0.002
Mean blood loss, cm3 (SD) 199.32 (191.81) 460.93 (276.29) 357.41 (277.23) < 0.0001
ORH 317.86 (302.94) 544.35 (309) 0.0006
MIS 171.67 (145.56) 359.51 (188.09) 0.0000
Hospital stay (HS), median (range) 3 (2–12) 8 (2–33) 5 (3–10) < 0.0001
ORH 6 (3–12) 9 (5–33) 0.0000
MIS 3 (2–7) 5 (2–32) 0.0000
LRH, laparoscopic radical hysterectomy; NA, not applicable; NSRH, nerve-sparing radical hysterectomy; Non-NSRH, non-
nerve-sparing radical hysterectomy; ORH, open radical hysterectomy; RRH, radical robotic hysterectomy; SD, standard 
deviation.
according to recent publications [27] we found that the 
NSRH group presented less urinary incontinence, loss of 
bladder filling sensation and straining of urinate compare 
to non- NSRH group although it did not reach statistical 
significance.
Our results show an association between NSRH 
and significant HS reduction. Morbidity reduction 
related to autonomic nerve plexus preservation as well 
as progressive improvement of the surgical technique 
with accumulated experience may account for these 
results. Nevertheless, we consider that the changes in 
the peri-operative management of these patients, with 
the progressive introduction of enhanced recovery after 
surgery (ERAS®) in our Gynecology Oncology unit in 
recent years, probably played a fundamental role in these 
results [28]. Our oncologic results in terms of OS, DFS, 
recurrences and cancer-specific mortality rates were 
similar between the two groups, as suggested by previous 
studies [24].
We know that there are some limitations in our 
study. First, it was conducted in a single centre and, 
therefore, it could be subject to biases derived from the 
technology and expertise available in our centre. Second, 
we had few patients to generate conclusive results in some 
aspects of the study. And third, as the study was carried 
out for more than 17 years there were unavoidable changes 
in the methodologies used. In contrast, one of the strengths 
of this work is that it reflects our long-term experience in 
these surgical techniques and the long follow-up of a large 
number of patients.
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Table 3: Morbidity data
Patients Intraoperative complications n = 34
≤ 30 Days complicationsa 
n = 37
Nerve-
sparing
75
2 vesical lesions (suture and prolonged 
urinary catheter) 
Grade II: n = 4
2 urinary infections
1 acute urine retention
1 abdominal wall infection
1 ureteral section (suture)
3 blood transfusions
Grade IIIa: n = 1
lymphocele (drainage)
Grade IIIb: n = 5
2 vaginal dehiscences (vaginal suture without 
complications)
1 urinoma secondary to ureteral lesion 
(secondary to sutured ureter) (laparotomy 
ureteroneocystostom)
2 abdominal eviscerations
Non-nerve 
sparing
1 vesical perforation
2 ureteral sections (ureteroneocystostomy)
Grade II n = 21
7 urinary infections
6 acute urine retention
5 ileus
3 abdominal wall infections
2 conversions to laparotomy (due to 
ureteral section)
1 anaphylactic shock secondary to 
Isosulfan Blue injection for SLN 
identification
Grade IIIb: n = 5
4 vaginal dehiscence (vaginal suture)1 urinary 
fistula
113 1 intestinal perforation Grade V: n = 1
Progressive multiorgan dysfunction secondary 
to massive intraoperative bleeding due to 
vascular lesion 
1 obturator vein lesion (bipolar 
coagulation and compression)
1 cava vein lesion (suture)
1 left internal Iliac vein lesion (Tissucol™ 
-Baxter AG, Vienna, Austria- and 
compression)
1 external iliac vein lesion (suture)
17 blood transfusions
Treatments within parentheses in italics. SLN, sentinel lymph node.
aClavien-Dindo Scoring System [20].
Table 4: Bladder and rectal function 12 months after surgery
NSRH (n = 75) Non-NSRH (n = 113) p-value 
Urinary incontinence 1 (1.3%) 4 (3.5%) 0.81
Loss of bladder filling sensation 1 (1.3%) 6 (5.3%) 0.48
Straining of urinate 3 (4%) 8 (7%) 0.76
constipation 2 (2.6%) 4 (3.5%) 0.55
Total 7 (9.3%) 22 (19.4%) 0.06
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Figure 1: Survival curves comparing NSRH with non-NSRH.
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MATERIALS AND METHODS
Patients
The study was approved by our institutional review 
board (PR (AMI) 23/1999) and in accordance with the 
Helsinki Declaration. All women provided informed 
consent for the surgical procedure, as well as for the 
recording and analysis of all relevant clinical data.
Between May 1999 and June 2016, all patients 
who were diagnosed with International Federation of 
Gynecology and Obstetrics (FIGO) stage IA2-IB1-IIA1 
cervical cancer who underwent an RH as first treatment 
at our institution were included in the study. Pregnant 
women and those patients who had received previous 
chemotherapy or pelvic radiotherapy were excluded from 
the study.
All patients had their initial pathologic diagnosis 
confirmed at our institution, following a cervical punch 
biopsy or a cone biopsy. Patients were staged according 
to the 2009 cervical cancer FIGO classification. 
Patients undergoing surgery before 2009, which had 
been initially staged according to the 1988 FIGO 
classification, were restaged according to the new 
2009 staging system [1, 2]. In all patients, magnetic 
resonance imaging was performed prior to surgery. The 
surgical complications were classified according to 
Dindo et al. [29]. 
Information of interest was recorded prospectively 
from the time of surgical indication to the last follow-up 
date recorded at the time of study closure.
Treatment
Nerve-sparing technique was first introduced in our 
institution in October 2006. Procedures performed before 
2006 were classified following the 1974 RH classification 
[30], and after the introduction of nerve-sparing technique, 
the new 2008 classification [15] was used accordingly. 
Patients with FIGO stage IA2 or IB1 with tumor size ≤ 2 
cm underwent proximal or modified RH (Piver type II) 
or type B1. Patients with FIGO stage IB1 with a tumor 
mass less than 2 cm on physical examination but with a 
larger mass on magnetic resonance imaging and those 
with a tumor mass larger than 2 cm underwent distal RH 
technique (Piver type III) or type C1.
The decision to perform a laparoscopic or open 
approach depended on the patient’s characteristics together 
with the surgeons’ and patients’ preferences. In 2009, with 
our center’s acquisition of one of the first robotic surgery 
devices in our country, robotic radical hysterectomy (RRH) 
was progressively introduced for performing RH. General 
exclusion criteria for the MIS approach (laparoscopic or 
robotic) include severe cardiorespiratory disease preventing 
a Trendelenburg position, enlarged uterus over 12 
gestational weeks, body mass index of 40 kg/m2 or higher, 
and age 80 years or older. The decision to use robotic 
surgery was also limited by the availability of the device.
Surgical technique
In the nerve-sparing technique (radical hysterectomy 
C1), the inferior hypogastric nerves, pelvic splanchnic 
Table 5: Recurrence data
NSRH
n = 75
Non-NSRH
n = 113
Total
n = 188
Recurrence location, n (%)
Vaginal 3 (23.08%) 3 (21.43%) 6 (21.4%)
Pelvic wall 5 (38.46%) 4 (21.43%) 9 (32.1%)
Peritoneal 1 (7.69%) 1 (7.14%) 2 (7.1%)
Supraclavicular lymph node 1 (7.69%) 0 1 (3.5%)
Distant metastasis 2 (15.38%) 1 (7.14%) 3 (10.7%)
Pelvic wall + vaginal 0 3 (21.43%) 3 (10.7%)
Pelvic wall + umbilical 0 1 (7.14%) 1 (3.5%)
Peritoneal + inguinal lymph node 0 1 (7.14%) 1 (3.5%)
Hepatic + vaginal 0 1 (7.14%) 1 (3.5%)
Pelvic wall + distant metastasis 1 (7.69%) 0 1 (3.5%)
Time of recurrence, n (%)
< 1 year 4 (30.8%) 6 (40%) 10 (35.7%)
< 2 years 7 (53.8%) 12 (80%) 19 (67.9%)
< 5 years 10 (76.9%) 14 (93.3%) 24 (85.7%)
Total, n (100%) 13 (100%) 15 (100%) 28 (100%)
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nerves, and inferior hypogastric plexuses with efferent 
nerves to the bladder and vagina are preserved, as 
opposed to the conventional technique. The key to 
optimal nerve preservation is the systematic identification 
of the anatomical structures of the autonomic nervous 
system. The minimally invasive approach can facilitate 
this surgical procedure in comparison to the laparotomic 
approach.
Three fundamental steps should be kept in mind 
when developing the NSRH technique (Figure 2). The 
Figure 2: Nerve-sparing radical hysterectomy: Key steps. R right side view of the pelvis; L left side view of the pelvis; B bladder; 
HN inferior hypogastric nerve; HP inferior hypogastric plexus; HV hypogastric vein; O Okabayashi space; OM intern obturator muscle; ON 
obturator nerve; P paracervical tissue; PR pararectal space; PV paravesical space; R rectum; SN pelvic splanchnic nerve (S2-S3); U ureter; 
US uterosacral ligament; UV deep uterine vein stump (hemolock); V vagina; VA superior vesical artery; VP vesical plexus; VV inferior and 
middle vesical veins; Y Yabuki space. (A) The pelvic splanchnic nerves are seen joining the HP in a perpendicular fashion, after sectioning 
the UV. (B) Distal fibers of the HP run toward the vagina and bladder along the dorsal vesicouterine ligament and the lateral wall of the 
vagina. (C) Pelvic autonomic nerves, nerve-sparing radical hysterectomy. (D) Isolation and preservation of the HN during dissection of the 
US and the Okabayashi space. (E) Dissection of the US and the Okabayashi space. (F) Dissection of the ureteral tunnel and Yabuki space.
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first step is to isolate and separate the deep uterine 
vein from the lower hypogastric plexus. After sentinel 
lymph node (SLN) identification and subsequent pelvic 
lymphadenectomy, the paravesical and pararectal spaces 
are dissected. This isolates the paracervical tissue 
that includes the uterine artery and the superficial and 
deep uterine veins. When dissecting, coagulating, and 
sectioning the deep uterine vein, ventral branches of the 
splanchnic nerves (S2-S3-S4) can be observed along its 
path toward the lower hypogastric plexus (Figure 2A–2C). 
The second step includes the isolation and preservation 
of the inferior hypogastric nerves, which are attached to 
the splanchnic nerves in the inferior hypogastric plexus, 
during dissection of the uterosacral ligament and the 
Okabayashi space (Figure 2D, 2E). Finally, the third step 
involves the preservation of the efferent bladder branches 
of the inferior hypogastric plexus, on the posterior leaf 
of the vesico-uterine ligament, during dissection of the 
Yabuki space. Visualization of the middle and lower 
vesical veins helps preserve these efferent branches 
(Figure 2F).
The surgical technique of open radical hysterectomy 
(ORH), laparoscopic radical hysterectomy (LRH), and RRH 
with and without a nerve-sparing approach together with the 
SLN identification procedure used by our group has been 
described in detail in previous publications [14, 31, 32].
Statistical analysis
Data are expressed as mean and standard deviation 
for normally distributed variables and as median and 
range of variables whose distribution departed from 
normality. Variables were tested for normality using the 
Kolmogorov-Smirnoff test. For qualitative variables, chi-
square and Fisher’s exact test were used. For quantitative 
variables, analysis of variance or Kruskal-Wallis test was 
used. Kaplan-Meier survival analyses were performed to 
estimate overall survival (OS), recurrence-free survival, 
and cancer-specific survival. Differences in the probability 
of survival according to the surgical procedure were 
compared using the log-rank test. Statistical significance 
was set at p < 0.05. STATA® 13.1 (StataCorp; College 
Station, TX, USA) was used for the statistical analysis.
CONCLUSIONS
In conclusion, our study showed that NSRH in 
early-stage cervical cancer is a feasible alternative. Our 
results indicate that it is associated with similar OS, 
DFS, recurrence rates, and cancer-specific mortality rates 
compared with non-NSRH.
This paper defines what has been the evolution of 
radical hysterectomy in the management of early-stage 
cervical cancer for the last two decades in our institution. 
We believe that the lack of data regarding OS and DFS 
after long periods of follow-up that conditioned the 
expansion of NSRH surgery has been properly addressed 
by the long follow-up period in this study. Properly 
designed prospective clinical trials about the subject would 
offer stronger evidence to support NSRH as the preferred 
approach for early-stage cervical cancer.
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